AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

The partners said their antibody-drug conjugate datopotomab deruxtecan didn’t extend survival in a breast cancer study, ...

AstraZeneca and Daiichi Sankyo have reported results from the TROPION-Breast01 Phase III clinical trial of datopotamab ...

A dark money anti-pharma bus —A rare disease treatment approval for Zevra —An FTC lawsuit against pharmacy benefit managers ...

It said the drug did not 'achieve statistical significance' in terms of the survival rates of those suffering from breast ...

Shares of Skye Bioscience gained after the San Diego biopharmaceutical company highlighted the safety of its in-development obesity treatment as compared with rivals. AstraZeneca shares slipped after ...

Daiichi Sankyo (OTCPK:DSKYF)(OTCPK:DSNKY) reports that more than 97% of eligible claimants have opted into the product liability settlement program related to olmesartan products... Daiichi Sankyo ...

Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan ...

PARIS: European shares closed higher on Monday as a soft business activity reading strengthened the case for more monetary ...